Kramer Jan-Niklas, Künzler Florian, Mishra Varun, Presset Bastien, Kotz David, Smith Shawna, Scholz Urte, Kowatsch Tobias
Center for Digital Health Interventions, Institute of Technology Management, University of St. Gallen, St. Gallen, Switzerland.
Center for Digital Health Interventions, Department of Management, Technology and Economics, Swiss Federal Institute of Technology, Zurich, Switzerland.
JMIR Res Protoc. 2019 Jan 31;8(1):e11540. doi: 10.2196/11540.
Smartphones enable the implementation of just-in-time adaptive interventions (JITAIs) that tailor the delivery of health interventions over time to user- and time-varying context characteristics. Ideally, JITAIs include effective intervention components, and delivery tailoring is based on effective moderators of intervention effects. Using machine learning techniques to infer each user's context from smartphone sensor data is a promising approach to further enhance tailoring.
The primary objective of this study is to quantify main effects, interactions, and moderators of 3 intervention components of a smartphone-based intervention for physical activity. The secondary objective is the exploration of participants' states of receptivity, that is, situations in which participants are more likely to react to intervention notifications through collection of smartphone sensor data.
In 2017, we developed the Assistant to Lift your Level of activitY (Ally), a chatbot-based mobile health intervention for increasing physical activity that utilizes incentives, planning, and self-monitoring prompts to help participants meet personalized step goals. We used a microrandomized trial design to meet the study objectives. Insurees of a large Swiss insurance company were invited to use the Ally app over a 12-day baseline and a 6-week intervention period. Upon enrollment, participants were randomly allocated to either a financial incentive, a charity incentive, or a no incentive condition. Over the course of the intervention period, participants were repeatedly randomized on a daily basis to either receive prompts that support self-monitoring or not and on a weekly basis to receive 1 of 2 planning interventions or no planning. Participants completed a Web-based questionnaire at baseline and postintervention follow-up.
Data collection was completed in January 2018. In total, 274 insurees (mean age 41.73 years; 57.7% [158/274] female) enrolled in the study and installed the Ally app on their smartphones. Main reasons for declining participation were having an incompatible smartphone (37/191, 19.4%) and collection of sensor data (35/191, 18.3%). Step data are available for 227 (82.8%, 227/274) participants, and smartphone sensor data are available for 247 (90.1%, 247/274) participants.
This study describes the evidence-based development of a JITAI for increasing physical activity. If components prove to be efficacious, they will be included in a revised version of the app that offers scalable promotion of physical activity at low cost.
ClinicalTrials.gov NCT03384550; https://clinicaltrials.gov/ct2/show/NCT03384550 (Archived by WebCite at http://www.webcitation.org/74IgCiK3d).
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/11540.
智能手机能够实施即时自适应干预(JITAIs),即根据用户和随时间变化的情境特征,随时间调整健康干预措施的提供方式。理想情况下,即时自适应干预应包括有效的干预组成部分,且干预措施的调整应基于干预效果的有效调节因素。利用机器学习技术从智能手机传感器数据中推断每个用户的情境,是进一步加强干预措施调整的一种有前景的方法。
本研究的主要目的是量化基于智能手机的身体活动干预措施的3个干预组成部分的主效应、交互作用和调节因素。次要目的是探索参与者的接受状态,即参与者更有可能通过收集智能手机传感器数据对干预通知做出反应的情况。
2017年,我们开发了“提升活动水平助手”(Ally),这是一款基于聊天机器人的移动健康干预措施,旨在通过激励、规划和自我监测提示来增加身体活动,以帮助参与者实现个性化的步数目标。我们采用微随机试验设计来实现研究目的。一家大型瑞士保险公司的被保险人受邀在12天的基线期和6周的干预期内使用Ally应用程序。登记后,参与者被随机分配到经济激励、慈善激励或无激励组。在干预期内,参与者每天被重复随机分配,以决定是否接受支持自我监测的提示,每周被随机分配,以决定是否接受两种规划干预措施中的一种或不接受任何规划。参与者在基线期和干预后随访时完成一份基于网络的问卷。
数据收集于2018年1月完成。共有274名被保险人(平均年龄41.73岁;57.7%[158/274]为女性)参与了本研究,并在其智能手机上安装了Ally应用程序。参与率下降的主要原因是智能手机不兼容(37/191,19.4%)和传感器数据收集(35/191,18.3%)。227名(82.8%,227/274)参与者有步数数据,247名(90.1%,247/274)参与者有智能手机传感器数据。
本研究描述了一种基于证据开发的用于增加身体活动的即时自适应干预措施。如果各组成部分被证明有效,它们将被纳入该应用程序的修订版,以低成本实现身体活动的可扩展推广。
ClinicalTrials.gov NCT03384550;https://clinicaltrials.gov/ct2/show/NCT03384550(由WebCite存档于http://www.webcitation.org/74IgCiK3d)。
国际注册报告识别号(IRRID):DERR1-10.2196/11540。